Purine Metabolism Regulates the Severity of APOL1 Nephropathy
Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2421-2434
DOI: 10.1681/asn.0000001129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 08.05.2026. Verfasst von Huihui Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Apolipoprotein L1, Purines, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIMHD NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Key Points Apolipoprotein L1 risk variants altered purine metabolic pathways. 5-aminoimidazole-4-carboxamide riboside supplementation alleviated apolipoprotein L1 risk variant–induced cytotoxicity.
Background
Thirteen percent of African American people have a high-risk apolipoprotein L1 ( APOL1) genotype, carrying two risk alleles (G1/G1, G1/G2, or G2/G2). The mechanisms underlying nephropathy caused by these APOL1 risk variant genotypes are not fully understood. Downstream of gene function, homeostatic maintenance of a complex and interconnected network of metabolites is essential for normal kidney function. However, this metabolic network can be rerouted by genetic changes or environmental insults, both of which can contribute to the development and/or progression of kidney diseases. APOL1 nephropathy exhibits both genetic and environmental triggers, but how APOL1 might alter metabolic homeostasis and how such changes may contribute to disease progression remains unclear.
Methods
APOL1 nephropathy was induced in human bacterial artificial chromosome transgenic APOL1 mice by IFN- γ adenovirus. Nontargeted metabolomics was performed on glomeruli from risk variant (G1/G1 and G2/G2) and nonrisk variant (G0/G0) mice as well as on tetracycline-inducible cell lines expressing risk or nonrisk variants. Metabolic signaling pathways in risk or nonrisk groups were compared, and transcriptional changes driving these metabolic differences were identified. Metabolic interventions were performed in both APOL1 risk and nonrisk variant–expressing cells and in mice. The effect of metabolic intervention was evaluated by cytotoxicity assays and urine albumin-to-creatinine ratios for cellular and in vivo responses, respectively.
Results
Perturbed purine metabolism was the strongest metabolite differentiator between high-risk and low-risk APOL1 genotypes in cultured cells and in whole glomeruli. Expression of APOL1 G2/G2 downregulated the rate-limiting enzymes of purine biosynthesis and induced ATP depletion. In APOL1 G2/G2-expressing cells, supplementation with the purine biosynthesis precursor 5-aminoimidazole-4-carboxamide riboside (AICAr) rescued purine biosynthesis, reduced cytotoxicity, and boosted ATP. In IFN- γ treated APOL1 G2/G2 transgenic mice, AICAr administration boosted purine biosynthesis, decreased kidney phosphorylated AMP-activated protein kinase, and reduced albuminuria levels. AICAr treatment rescued G2 mouse podocyte death induced by the inflammatory stimuli of combined IFN- γ and toll-like receptor 1/2 agonist.
Conclusions
Increasing purine biosynthesis mitigated APOL1 risk variant–induced injury in cell and transgenic mouse models of APOL1 kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
- Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
ORCID-Profile: Huihui Huang, Calum Tattersfield, Esilida S Karreci, Aarya Rumde, Lauren Francey, Balajikarthick Subramanian, Birgitta Ryback, Valerie Schumacher, Seth L Alper, Zsuzsanna K Zsengellér, Martin R Pollak, David J Friedman
Förderung
- NIDDK NIH HHS
- NIMHD NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Huang, H., Tattersfield, C., Jacas, S., Karreci, E. S., Rumde, A., Kelly, J., Francey, L., Subramanian, B., Huang, M., Ryback, B., Schumacher, V., Alper, S. L., Zsengellér, Z. K., Pollak, M. R., & Friedman, D. J. (2026). Purine Metabolism Regulates the Severity of APOL1 Nephropathy. Journal of the American Society of Nephrology, 37(11), 2421-2434. https://doi.org/10.1681/asn.0000001129
Vancouver
Huang H, Tattersfield C, Jacas S, Karreci ES, Rumde A, Kelly J, et al. Purine Metabolism Regulates the Severity of APOL1 Nephropathy. Journal of the American Society of Nephrology. 2026;37(11):2421-2434. doi:10.1681/asn.0000001129
BibTeX
@article{Huang2026,
author = {Huang, Huihui and Tattersfield, Calum and Jacas, Sonako and Karreci, Esilida S and Rumde, Aarya and Kelly, Jessica and Francey, Lauren and Subramanian, Balajikarthick and Huang, Ming and Ryback, Birgitta and Schumacher, Valerie and Alper, Seth L and Zsengellér, Zsuzsanna K and Pollak, Martin R and Friedman, David J},
title = {Purine Metabolism Regulates the Severity of APOL1 Nephropathy},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {11},
pages = {2421--2434},
doi = {10.1681/asn.0000001129}
}
EUVIMED